Network analyses in systems pharmacology

Bioinformatics

Volumn 25, Issue 19, 2009, Pages 2466-2472

  Berger, Seth I ^a   Iyengar, Ravi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DASATINIB; IMATINIB; TAMOXIFEN;

CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC SUSCEPTIBILITY; INFORMATION PROCESSING; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SYSTEMS BIOLOGY; SYSTEMS PHARMACOLOGY; TRANSCRIPTION REGULATION;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG DISCOVERY; GENE REGULATORY NETWORKS; SYSTEMS BIOLOGY;

EID: 70349847876     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btp465     Document Type: Review

References (49)

1. Barabasi,A.L. and Albert,R. (1999) Emergence of scaling in random networks. Science, 286, 509-512.
2. Berger,S.I. et al. (2007) Genes2Networks: Connecting lists of gene symbols using mammalian protein interactions databases. BMC Bioinformatics, 8, 372.
3. Bromberg,K.D. et al. (2008) Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science, 320 903-909.
4. Camargo,L.M. et al. (2007) Disrupted in Schizophrenia 1 Interactome: Evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry, 12 74-86.
5. Campillos,M. et al. (2008) Drug target identification using side-effect similarity. Science, 321, 263-266.
6. Chen,J. et al. (2009) Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics 10, 73.
7. Chu,L.H. and Chen,B.S. (2008) Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets. BMC Syst. Biol., 2, 56.
8. Dasika,M.S. et al. (2006) A computational framework for the topological analysis and targeted disruption of signal transduction networks. Biophys J., 91, 382-398.
9. Durmus Tekir,S. et al. (2009) Drug targets for tumorigenesis: insights from structural analysis of EGFR signaling network. J. Biomed. Inform., 42, 228-236.
10. Fatumo,S. et al. (2009) Estimating novel potential drug targets of Plasmodium falciparum by analysing the metabolic network of knock-out strains in silico. Infect. Genet. Evol., 9, 351-358.
11. Goh,K.I. et al. (2007) The human disease network. Proc. Natl Acad. Sci. USA, 104, 8685-8690.
12. Hansen,N. et al. (2009) Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther., 86, 183-189.
13. Hert,J. et al. (2008) Quantifying the relationships among drug classes. J. Chem. Inf. Model, 48, 755-765.
14. Hoffmann,P. and Warner,B. (2006) Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods, 53 87-105.
15. Hwang,S. et al. (2008a)Aprotein interaction network associated with asthma. J. Theor. Biol., 252, 722-731.
16. Hwang,W.C. et al. (2008b) Identification of information flow-modulating drug targets: A novel bridging paradigm for drug discovery. Clin. Pharmacol. Ther., 84, 563-572.
17. Hyduke,D.R. et al. (2007) Integrated network analysis identifies nitric oxide response networks and dihydroxyacid dehydratase as a crucial target in Escherichia coli. Proc. Natl Acad. Sci. USA, 104, 8484-8489.
18. Iorio,F. et al. (2009) Identifying network of drug mode of action by gene expression profiling. J. Comput. Biol., 16, 241-251.
19. Jeong,H. et al. (2000) The large-scale organization of metabolic networks. Nature, 407, 651-654.
20. Jeong,H. et al. (2001) Lethality and centrality in protein networks. Nature, 411, 41-42.
21. Jovelin,R. and Phillips,P.C. (2009) Evolutionary rates and centrality in the yeast gene regulatory network. Genome Biol., 10, R35.
22. Keiser,M.J. et al. (2007) Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 25, 197-206.
23. Kohler,S. et al. (2008) Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet., 82, 949-958.
24. Lim,J. et al. (2006) A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell, 125, 801-814.
25. Luo,F. et al. (2007) Modular organization of protein interaction networks. Bioinformatics, 23, 207-214.
26. Ma'ayan,A. et al. (2005) Formation of regulatory patterns during signal propagation in a Mammalian cellular network. Science, 309, 1078-1083.
27. Ma'ayan,A. et al. (2007) Network analysis of FDA approved drugs and their targets. Mt. Sinai. J. Med., 74, 27-32.
28. Macpherson,J.I. et al. (2009) JNets: Exploring networks by integrating annotation. BMC Bioinformatics, 10, 95.
29. Milo,R. et al. (2002) Network motifs: Simple building blocks of complex networks. Science, 298, 824-827.
30. Muller,M. et al. (2008) Network topology determines dynamics of the mammalian MAPK1,2 signaling network: Bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J., 22, 1393-1403.
31. Nacher,J.C. and Schwartz,J.M. (2008)A global view of drug-therapy interactions. BMC Pharmacol., 8, 5.
32. Ozgur,A. et al. (2008) Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics, 24, i277-i285.
33. Qu,X.A. et al. (2009) Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics, 10 (Suppl. 5), S4.
34. Raman,K. and Chandra,N. (2008) Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance. BMC Microbiol., 8, 234.
35. Ruths,D.A. et al. (2006) Hypothesis generation in signaling networks. J. Comput. Biol., 13, 1546-1557.
36. Singh,S. et al. (2007) Choke point analysis of metabolic pathways in E.histolytica: A computational approach for drug target identification. Bioinformation, 2, 68-72.
37. Sridhar,P. et al. (2007) An iterative algorithm for metabolic network-based drug target identification. Pac. Symp. Biocomput., 12, 88-99.
38. Sridhar,P. et al. (2008) Mining metabolic networks for optimal drug targets. Pac. Symp. Biocomput., 13, 291-302.
39. Stites,E.C. et al. (2007) Network analysis of oncogenic Ras activation in cancer. Science, 318, 463-467.
40. Tanaka,T. et al. (2008) Pharmacogenomics of cardiovascular pharmacology: Pharmacogenomic network of cardiovascular disease models. J. Pharmacol. Sci., 107, 8-14.
41. Towfigh,S. et al. (2002) Outcomes from peptic ulcer surgery have not benefited from advances in medical therapy. Am. Surg., 68 385-389.
42. Vinogradov,A.E. (2009) Global versus local centrality in evolution of yeast protein network. J. Mol. Evol., 68, 192-196.
43. Wang,H. et al. (2008) Betweenness centrality in a weighted network. Phys Rev. E Stat. Nonlin. Soft Matter Phys, 77 (Pt 2), 046105.
44. Wishart,D.S. et al. (2008) DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 36, D901-D906.
45. Wuchty,S. et al. (2003) Evolutionary conservation of motif constituents in the yeast protein interaction network. Nat. Genet. 35, 176-179.
46. Xie,L. et al. (2009) Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of cetp inhibitors. PLoS Comput. Biol., 5, e1000387.
47. Xing,H. and Gardner,T.S. (2006) The mode-of-action by network identification (MNI) algorithm: A network biology approach for molecular target identification. Nat. Protoc., 1, 2551-2554.
48. Yeh,P. et al. (2006) Functional classification of drugs by properties of their pairwise interactions. Nat. Genet., 38, 489-494.
49. Yildirim,M.A. et al. (2007) Drug-target network. Nat. Biotechnol., 25, 1119-1126.